# DePuy Synthes signs exclusive distribution agreement with CGBIO for NOVOSIS

DePuy Synthes entered an exclusive distribution agreement with CGBIO for NOVOSIS, an advanced bone graft substitute containing growth factors, for spine, craniomaxillofacial, and trauma portfolios in the United States, Canada, and Australia.

- Type: Contract
- Announced: 2026-05-27
- Where: United States
- Status: announced
- Products: bone graft substitute, NOVOSIS
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [DePuy Synthes](https://endata.com/companies/21191.md)
- [DePuy Synthes](https://endata.com/companies/21191.md) (customer)
- [CGBIO](https://endata.com/companies/42255.md) (supplier)

## Sources

- [g-medtech.com](https://g-medtech.com/news/depuy-synthes-announces-two-strategic-agreements-to-expand-orthopaedic-portfolio/), 2026-05-27: "Separately, it has entered an exclusive distribution agreement with CGBIO for NOVOSIS, an advanced bone graft substitute containing growth factors, across its spine, craniomaxillofacial, and trauma portfolios."
- [healthindustryhub.com.au](https://www.healthindustryhub.com.au/medical-technology-news-trends/depuy-synthes-strikes-deal-ahead-of-split-from-johnson-johnson/), 2026-06-16: "DePuy Synthes has entered into an exclusive distribution agreement with CGBIO covering the development and commercialisation of Novosis, an advanced bone graft substitute containing growth factors."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.